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Legionella pneumophila, the agent of Legionnaires' disease, is a facultative intracellular 
pathogen  (1).  The  bacterium  multiplies  intracellularly  in  human  monocytes,  and 
under tissue culture conditions, multiplication  is exclusively intraeellular  (1). 
In previous studies, we investigated the role of humoral immunity in Legionnaires' 
disease  (2,  3).  We  found  that  virulent  in  vivo  grown  L.  pneumophila  bacteria  are 
completely resistant  to the bacteriocidal effects of human serum even in the presence 
of high-titer anti-L, pneumophila antibody (2). The bacteria also resist killing by freshly 
explanted human polymorphonuclear leukocytes and monocytes even in the presence 
of specific antibody and  complement;  under optimal  conditions,  only 0.5  log of an 
inoculum  is killed by these phagocytes (2, 3).  Most importantly,  L. pneumophila bind 
more avidly to monocytes in the presence of specific antibody and complement, but 
the bacteria  multiply intracellularly  as rapidly as when they enter monocytes in the 
absence of antibody  (3).  These  results  indicate  that  humoral  immunity,  at  least  by 
itself, does not play a  decisive role in host defense against Legionnaires' disease. 
In  this  study,  we  investigate  the  potential  role  of cell-mediated  immunity  in 
Legionnaires' disease.  We demonstrate  that  (a)  in vitro activated  human  monocytes 
have the capacity to inhibit the multiplication of virulent L. pneumophila;  (b) cytokines 
produced by mitogen-sensitized  human mononuclear cell cultures have the capacity 
to activate  the  monocytes such  that  they can  inhibit  L.  pneumophila  multiplication; 
and  (c) activated monocytes inhibit  L. pneumophila multiplication  both by decreasing 
phagocytosis and by decreasing the rate of intracellular multiplication. 
Materials  and Methods 
Media.  Egg  yolk  buffer,  with  or  without  1%  bovine  serum  albumin,  and  RPMI  1640 
medium were prepared or obtained as described previously (1). No antibiotics were added to 
any medium in any of the experiments. 
Reagents.  Concanavalin A (Con A) 1, three times crystallized and lyophilized, was obtained 
from Miles-Yeda Ltd., Kankakee, Ill.. 
Agar.  Modified charcoal yeast extract  agar was prepared  in  100- ×  15-mm bacteriologic 
petri dishes  as described (1). 
Serum.  Venous blood was obtained and clotted, and the serum was separated and stored at 
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-70°C  until  used  as  described  (4).  Normal  (nonimmune)  human  serum  (type AB)  with  an 
indirect fluorescent antibody (IFA) anti-L, pneumophila titer (5) of < 1:64 was obtained from an 
adult donor not known to have ever had Legionnaires' disease. Immune human serum with an 
IFA anti-L, pneumophila titer of 1:4,096  was obtained  from an adult  donor who had  recently 
recovered from Legionnaires' disease (2). 
Bacteria.  L.  pneumophila,  Philadelphia  1  strain,  was  grown  in  embryonated  hens'  eggs, 
harvested, tested for viability and for the presence of contaminating bacteria, stored at -70°C, 
and partially purified by differential centrifugation just before use, as described (1). 
Human Blood Mononuclear Cells.  Mononuclear cells used in experiments with L. pneumophila 
were obtained from the blood of a normal adult donor not known to have ever had Legionnaires' 
disease and with an IFA anti-L, pneumophila titer of < 1:64. The blood mononuclear cell fraction 
was obtained by centrifugation over a Ficoll-sodium diatrizoate solution as previously described 
(1); the cells were >99% viable by trypan blue exclusion. Examination of a stained cytocentri- 
fuged sample  revealed that  the mononuclear cell fraction contained  -40% monocytes, 58.5% 
lymphocytes, and  1.5% polymorphonuclear leukocytes. The adherent subpopulation  (contain- 
ing >90% monocytes) was prepared as described (1).  Mononuclear cells used in the production 
of Con A-induced supernatants were obtained from the burly coat of blood donated at the New 
York Blood Center. The buffy coat cells were diluted  1:1  in 0.9% saline and the mononuclear 
cells were obtained as  from blood by centrifugation  over a  Ficoll-sodium diatrizoate solution 
(1). 
Assay for Activation of Monocytes in Cultures Containing Con A  and Lymphocytes.  6  ×  106 freshly 
explanted mononuclear cells (~40% monocytes; ~60% lymphocytes) were incubated in 35-mm 
plastic petri dishes in 2 ml RPMI  1640 medium containing 25% fresh normal human serum for 
1.5 h  at 37°C to allow monocytes to adhere to the dishes.  At this point  in some experiments, 
control dishes were washed vigorously to remove the nonadherent lymphocyte-enriched fraction 
of the  mononuclear  cell population,  leaving adherent  cells that  were >90%  monocytes. The 
monocytes, in the presence or absence of lymphocytes, were then incubated for 24 h at 37°C in 
5%  CO2-95%  air with  Con  A  at  concentrations  ranging  from 0  to 32 /~g/ml as  indicated  in 
Results.  After 24 h,  L pneumophila  (2  ×  104 colony-forming units  [CFU])  were added  to  the 
cultures. L. pneumophila were not agglutinated by Con A  at concentrations up to  1,000/~g/ml. 
The  cultures  were  incubated  at  37°C  in  5%  CO2-95%  air on a  gyratory  shaker  for  1 h  and 
under stationary conditions thereafter. CFU of L. pneumophila in each culture were determined 
daily as described (1). 
Preparation of Supernatants of Con A-sensitized Mononuclear Cell Cultures. 6 ×  106 mononuclear cells 
were incubated in 35-mm plastic petri dishes at 37°C in 5% CO2-95% air for 0, 24, 48, or 72 h 
in 2 ml RPMI  1640 medium containing 25% fresh normal human serum and 0-32/xg/ml Con 
A. At the end of the incubation,  the cultures  were transferred  to conical  tubes  and  the cells 
were sedimented by centrifugation at 200 g for 10 min at 4°C. The supernatant  was removed, 
filtered  through  0.2  ~m  Millipore  filters  (Millipore  Corp.,  Bedford,  Mass.),  and  stored  at 
-70°C. 
Assay  for  Activation  of  Monocytes  with  Supernatant  of  Con  A-sensitized  Mononuclear  Cell 
Cultures.  Mononuclear cells (6 ×  106) were incubated  in  35-mm petri  dishes in  2 ml  RPMI 
1640 medium containing  10% serum for 1.5 h  at 37°C in 5% COz-95% air to allow monocytes 
to adhere.  The dishes  were then  vigorously washed  to remove the nonadherent  lymphocyte- 
enriched  fraction  of the mononuclear cell population.  The  monocyte  monolayers  were then 
incubated  for 0,  12,  24,  or 48  h  in  2  ml  RPMI  1640  medium  containing  15%  fresh  normal 
human serum and 0-40% (vol/vol) of Con A-induced supernatant  prepared as described above. 
In some experiments, control monocyte monolayers were incubated with 20%  (vol/vol) super- 
natant of mononuclear cell cultures from which Con A was omitted and/or with 20% (vol/vol) 
solution of Con A at  16/Lg/ml (final concentration 3.2 p,g/ml Con A). Monoeytes incubated for 
48  h  with  any  of these  supernatant  preparations  or control  solutions  were  >99%  viable by 
trypan  blue exclusion.  24 or 48  h  after explantation  of monoeytes, L. pneumophila (~2  ×  104 
CFU) were added to the cultures. The cultures were incubatedat  37°C in 5% CO2-95% air on 
a  gyratory shaker for  1 h  and under stationary conditions thereafter. CFU of L. pneumophila in 
each  culture  were  determined  daily,  as  described  (1).  In  some experiments,  leukocytes  were 
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volume) additional fresh Con A-induced supernatant  or control medium was added to cultures 
daily after infection. 
Assays  for the Binding or Ingestion of L. pneumophila by Supernatant-activated  Monocytes.  Monocytes 
in  monolayer culture  were prepared  as  in  the assay  described  above.  The  monolayers  were 
incubated  for 24 h  at 37°C in 5% CO2-95% air in 2 ml RPMI  1640 medium containing  15% 
fresh normal human serum and 20% Con A-induced supernatant  or control medium. After 24 
h, L. pneumophila (5 ×  105 CFU) were added to each petri dish and the cultures were incubated 
for  2  h  at  37°C  in  5%  CO2-95%  air  on  a  gyratory  shaker  at  100  rpm.  At  the  end  of the 
incubation, the monolayers were vigorously washed four times to remove nonadherent bacteria. 
Two  assays  were  then  performed  in  parallel.  First,  to  determine  the  number  of viable  L. 
pneumophila bound or ingested, the mean CFU/monocyte was calculated from the number of 
adherent  monocytes and CFU in each petri dish. The number of adherent  monocytes in each 
dish was determined by counting monocytes within a calibrated area using an inverted phase- 
contrast  microscope; counts  from four different areas of each dish were averaged. CFU were 
determined after lysing the monocytes by sonication. 
Second, to determine the number of L. pneumophila bacterial particles bound or ingested, a 
fluorescent assay was used. Replicate monocyte monolayers were infected and washed as above, 
and  then  fixed, stained  with fluorescein-conjugated rabbit  anti-L, pneumophila antiserum,  and 
examined  by  fluorescence microscopy as  described  (1).  The  number  of fluorescent  bacterial 
particles  bound  to  or  ingested  by  >1,400  consecutive  supernatant-activated  and  control 
monocytes and the percentage of these monocytes with ~ 1 cell-associated bacterial particle was 
enumerated  microscopically.  From  these  data,  the  average  number  of bacterial  particles/ 
monocyte was calculated in each experiment. 
Electron Microscopy.  Monocyte monolayers were prepared, infected, and washed as described 
in the previous assay except that  the monolayers were infected with  7.5  x  107 CFU (3 X  108 
bacterial particles) of agar-grown L. pneumophila instead of egg yolk-grown bacteria. The agar- 
grown bacteria were obtained by culturing egg yolk-grown L. pneumophila on modified charcoal 
yeast  extract  agar  for  72  h.  These  bacteria  were  25%  viable as  determined  by counting the 
number  of  bacterial  particles,  using  a  Petroff-hausser  chamber  (Arthur  H.  Thomas  Co., 
Philadelphia, Pa.) and measuring the number of CFU in a suspension of the bacteria. After the 
monocyte  monolayers  were  washed  free  of nonadherent  bacteria,  they  were  processed  for 
electron microscopy as described (1). 
Determination  of  Doubling  Times  of  L.  pneumophila  in  Supernatant-activated and  Control 
Monocytes.  Replicate  monocyte  monolayers  were  prepared,  infected,  and  washed  free  of 
nonadherent bacteria as in Assays  for the Binding or Ingesting of L. pneumophila by Supernatant-activated 
Monocytes described  above.  In  the  same  way  that  CIFU  per  petri  dish  were  determined 
immediately after infection in that  assay  (after lysing the monocytes by sonication), CFU per 
petri dish were determined 22 h  after infection in this assay. Both data were used to compute 
the doubling time. The doubling time was determined from the formula 
(t -  t0)log 2 
doubling time -- 
where  to  is  the  time  of  the  first  determination  of CFU/dish,  t  is  the  time  of  the  second 
determination  (22 h  later)  Nt is the number of CFU/dish at time t, and No is the number of 
CFU/dish at time to. 
Assay for  Killing  of  L.  pneumophila  by  Monocytes Activated with  Con  A-induced Superna- 
rant.  Mononuclear cells (6 ×  106) suspended  in  1.5 ml RPMI  1640  medium containing 20% 
fresh normal human serum were incubated in plastic test tubes with or without 200 #1 Con A- 
induced supernatant  for 24 h  at  37°C in 5% CO2-95% air. After 24 h,  200/~1  Con A-induced 
supernatant  was added  to cultures to which it had not been added  initially. At this point,  L. 
pneumophila were incubated  for 10 min at 37°C in RPMI  1640  medium containing either 25% 
normal  or 25%  immune  fresh  human  serum.  Then  106 CFU in  100  #1  of this  medium  were 
added to the mononuclear cell cultures. Normal or immune fresh human serum (200 #1) of the 
same type in which the L. pneumophila were preincubated  was also added to cultures, bringing 
the final volume to 2 ml. The tubes were gassed with 5% CO2-95% air so that  the pH was 7.4, MARCUS  HORWITZ  AND  SAMUEL  SILVERSTEIN  1621 
as judged  by the  phenol  red  indicator  dye,  capped,  sealed  with  Parafilm  (American  Can 
Company, Greenwich, Conn.), and incubated for 2 h at 37°C on a gyratory shaker at 300 rpm. 
At the end of the incubation, the tubes were placed in an ice-water bath to stop the reaction 
and sonicated for 30 s continuously as described (1, 3). CFU in the medium were determined 
as described (1). 
Sonication of Infected Monoqte and Mononudear Cell Cultures.  This was performed essentially as 
described (1, 3). The amount of sonic energy used lysed the leukocytes completely but did not 
reduce bacterial CFU (1, 3). 
Results 
Monocytes Incubated with Both  Con A  and Lymphocytes Acquire the Capacity to Inhibit the 
Intracellular Multiplication  of L. pneumophila.  We incubated  freshly explanted  human 
peripheral blood monocytes in monolayer culture for 24 h in medium containing Con 
A (16 #g/ml), autologous peripheral blood lymphocytes, both Con A and lymphocytes, 
or neither Con A  nor lymphocytes as described in Materials  and Methods.  We then 
added virulent L. pneumophila  to each culture and determined CFU daily. L. pneumo- 
phila  multiplied  several  logs in control cultures, but  multiplication  was inhibited  in 
cultures  containing  both  Con  A  and  lymphocytes  (Fig.  1).  The  inhibition  was  of 
intracellular  multiplication  in  monocytes  because  L.  pneumophila  multiplies  only 
intracellularly  under tissue culture conditions (1). 
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Fro.  1.  Monocytes incubated with both Con A  and lymphocytes inhibit L. pneumophila multipli- 
cation.  Mononuclear cells  (6  ×  106) in  2  ml  medium containing 25%  fresh human serum were 
incubated in 35-mm plastic petri dishes for 1.5 h at 37°C in 5% CO2-95% air to allow monocytes to 
adhere. Some cultures were vigorously washed to remove nonadherent (predominantly lymphoid) 
cells. These and the other cultures were then further incubated for 24 h with or without Con A (16 
#g/ml). L. pneumophila (2 X  104 CFU)  were then added to each culture and CFU in each culture 
determined daily. Each point represents the average for three replicate petri dishes :1: SE. 1622  ACTIVATED MONOCYTES  INHIBIT LEGIONELLA  MULTIPLICATION 
To determine the effect of Con A  concentration on mononuclear cell inhibition of 
L. pneumophila multiplication, we incubated mononuclear cells with Con A  in concen- 
trations ranging from 0  to  16/xg/ml  for 24 h.  We then  infected the cultures with L. 
pneumophila  and  determined  CFU  daily as above.  Con  A  exhibited a  dose-response 
pattern in sensitizing mononuclear cells to inhibit L. pneumophila multiplication (Fig. 
2).  In the experiment described in Fig. 2,  multiplication was somewhat  inhibited in 
cultures  containing  0.5  and  1 ffg/ml  Con  A  and  maximally  inhibited  in  cultures 
containing  -->2 /~g/ml  Con  A.  In  several  experiments  of  this  type,  Con  A  was 
consistently maximally effective at ->4 #g/ml. 
These studies show that  monocytes in Con A-sensitized monontlclear cell cultures 
acquire  the  capacity  to  inhibit  the  multiplication  of L.  pneumophila  and  that  this 
phenomenon  is lymphocyte dependent. This suggested the possibility that a  cytokine 
produced  in  the  Con  A-sensitized mononuclear  cell  cultures  might  be  involved  in 
functionally altering the monocytes such  that  they can  inhibit L. penumophila  multi- 
plication. We shall refer to this functional alteration as "activation." We investigated 
this possibility next. 
Monocytes Incubated with Cell-free Supernatant of Con A-sensitized  Mononuclear Cell Cultures 
Acquire  the  Capacity  to  Inhibit  the  Intracellular  Multiplication  of  L.  pneumophila.  We 
incubated  monocyte  monolayers,  which  had  been  vigorously  washed  to  remove 
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FIG. 2.  Con A exhibits a dose-response pattern in sensitizing mononuclear cells. Mononuclear cells 
(6 ×  106) in 2 ml medium containing  25% serum were incubated  with Con A at concentrations 
ranging from 0 to 16/.tg/ml for 24 h at 37°C in 5% CO2-95% air. L. pneumophila (2 X 104 CFU) were 
then  added to each culture and CFU in each culture determined  daily as in Fig. 1. Each point 
represents the average for three replicate petri dishes + SE. MARCUS HORWITZ AND SAMUEL SILVERSTEIN  1623 
nonadherent cells (predominantly lymphocytes), in medium containing 0-40% cell- 
free filtered supernatant of mononuclear cell cultures sensitized for 48 h with  15 #g/ 
ml Con A  (see Materials and Methods). After 24 h, we added L. pneumophila to the 
cultures. Monocytes treated with supernatant from Con A-sensitized mononuclear cell 
cultures  inhibited  L.  pneumophila multiplication,  and  the  degree of inhibition  was 
proportional to the concentration of supernatant added (Fig. 3). 
We examined activated and nonactivated monocyte monolayers by phase contrast 
microscopy and  noted  striking  differences in  the  integrity of the  monolayer after 
infection with L. pneumophila. By 48 h  after infection, control monocyte monolayers 
were destroyed but activated monocyte monolayers were intact. 
Because supernatant-activated monocytes averaged twice the size of nonactivated 
monocytes  (see  below),  it  was  possible  that  the  reduced  CFU  in  the  medium  of 
activated monocytes was to some extent due to sequestration of L. pneumophila within 
activated monocytes. We therefore performed control experiments in which we lysed 
replicate  monocyte cultures  by  sonication  to  release  intracellular  bacteria  before 
assaying the culture medium for CFU; sonication at the Levels used has no effect on 
the viability of L. pneumophila (1).  Sonication did not significantly increase CFU  in 
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Fie.  3.  Monocytes incubated with the supernatant of Con A-sensitized mononuclear cell cultures 
inhibit L. pneumophila multiplication.  Monocytes in monolayer culture were incubated at  37°C in 
5%  CO2-95% air in  2  ml RPMI  1640 medium containing  15%  fresh normal human serum and 
0-40% cell-free supernatant from Con A-sensitized mononuclear cell cultures. Control monolayers 
were incubated with supernatant from a  mononuclear cell culture from which Con A was omitted 
(supernatant control) or with  15 #g/ml Con A  (Con A control). After 24 h, L. pneumophila (2 ×  104 
CFU) were added to the cultures and CFU in each culture determined daily. Each point represents 
the average for three replicate petri dishes +  SE. 1624  ACTIVATED  MONOCYTES  INHIBIT LEGIONELLA  MULTIPLICATION 
these cultures, whether or not the monocytes were activated. Thus, L. pneumophila were 
not sequestered within the activated monocytes. 
We concluded  from these experiments that cytokines released into the medium of 
Con A-sensitized mononuclear cell cultures have the capacity to activate monocytes 
such  that  they  inhibit  L.  pneumophila  multiplication.  We  next  sought  to  define 
experimental conditions for generating supernatants with enhanced potency. 
Supernatant Potency Is Proportional to the Concentration of Con A  Used for Sensitization of the 
Mononuclear Cell  Cultures and Maximal  after 48 h of Sensitization.  We  first  studied  the 
effect on supernatant potency of varying the concentration of Con A used to sensitize 
the mononuclear cell cultures. We prepared five different supernatants by incubating 
mononuclear cells  for 48  h  with  five concentrations of Con A  ranging  from 0  to  15 
#g/ml.  We  then  tested  these supernatants  for their capacity  to activate  monocytes 
such that they could inhibit L. pneumophila multiplication, as described  in the legend 
to Fig. 4. 
The capacity of supernatant-activated  monocytes to inhibit  L. pneumophila multi- 
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FiG.  4.  Supernatant  potency  is proportional to the concentration  of Con A  used for sensitization 
of the  mononuclear  cell cultures.  Five different  supernatants  were prepared by  incubating  mono- 
nuclear cells with Con A  at concentrations of 0, t, 4, 8, and  15/zg/m], as described in Materials and 
Methods. Then  freshly explanted  monocytes  in monolayer culture  were  incubated  in 2 ml  RPMI 
|640  medium  containing  15%  fresh normal  human  serum  and  20%  (vol/vol)  of the supernatant 
preparation  indicated.  An additional  set  of control  monocyte  monolayers was similarly  incubated 
in medium  containing  20% (vol/vol) solution of Con A  at  15/~g/ml  (Con A  control). After 24 h, L. 
pneumophila  (2 X  104 CFU)  were added to each culture and CFU  in each culture determined  daily. 
In  this experiment,  200 #1 of fresh  supernatant  or control  Con  A-containing  solution  of the same 
type  as  used  initially  was  added  to each  culture  daily  after  infection.  Each  point  represents  the 
average for three replicate petri dishes +  SE. MARCUS HORWITZ AND SAMUEL SILVERSTEIN  1625 
plication  was  proportional  to  the  concentration of  Con  A  used  to  generate  the 
supernatants up to  15/.tg/ml Con A  (Fig. 4). 
In  other  experiments,  we  compared  four  different  supernatants,  prepared  by 
incubating mononuclear cells with  15/~g/ml Con A  for 0, 24, 48, or 72 h, and found 
that the 48-h supernatants endowed monocytes with the greatest capacity to inhibit 
L. pneumophila multiplication. Consequently, in all subsequent experiments, we used 
supernatants generated with  15/tg/ml Con A  for 48 h. 
Optimal Conditions for Activating Monocytes with Con A-induced Supernatant.  We found 
that  the degree of rnonocyte inhibition of L. pneumophila multiplication was propor- 
tional  to  the  length  of  time  monocytes  were  preincubated with  Con  A-induced 
supernatant (48 h  >  24 h  >  12 h)  before infection (data not shown). We also found 
that monocytes treated repeatedly with fresh supernatant had an enhanced capacity 
to inhibit L. pneumophila multiplication (Fig. 5). 
Monocytes Progressively Lose Responsiveness to Con A-induced Supernatant and Spontaneous 
Inhibitory Capacity with  Time  in Culture.  Monocytes kept  in culture differentiate and 
come to resemble tissue macrophages  (6).  To determine whether monocytes kept  in 
culture retain their capacity to respond to cytokines with inhibition of L. pneumophila 
multiplication, we cultured monocytes for 0, 3,  7, or  10 d  before treating them with 
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Fxc.  5.  Monocytes  treated  repeatedly with Con  A-induced supernatant  inhibit L. pneumophila 
multiplication more than monocytes treated only before infection. Freshly explanted monocytes in 
monolayer culture were incubated in RPMI  1640 medium containing 15% fresh normal human 
serum. Some cultures were treated with Con A-induced supernatant  (200 btl or  10% by volume) 
immediately after explantation and with control supernatant every 24 h thereafter (supernatant 
initially only). Other cultures were treated with Con A-induced supernatant  (200 ,ttl) every 24 h 
(supernatant Q24H) or every 12 h (supernatant Q12H). Control cultures were treated every 24 h 
with 200 #1 control supernatant  (supernatant control Q24H) or 200 ~1 Con A (15 ,ttg/ml) solution 
(Con  A control Q24tt).  L. pneumophila (2  ×  104 CFU)  were added  to  all cultures 24  h  after 
explamation, and CFU were determined daily. Each point represents the average for three replicate 
pelri dishes + SE. 1626  ACTIVATED  MONOCYTES  INHIBIT  LEGIONELLA  MULTIPLICATION 
Con A-induced supernatant or control medium. We infected the monocytes 24 h after 
their first treatment. 
With time in culture, monocytes progressively lost their reponsiveness to superna- 
tant, that is, they exhibited a  diminished capacity to inhibit L. pneumophila multipli- 
cation  (Fig. 6 A). Interestingly, control monocytes also became less  inhibitory to L. 
pneumophila multiplication (Fig. 6 B). Whereas, in freshly explanted control monocytes, 
L. pneumophila did not multiply above the level of the initial inoculum until 24-48 h 
after infection, in control monocytes cultured >--3 d, L. pneumophila multiplied 0.75-1.5 
log above the level of the initial inoculum during the first 24 h  after infection (Fig. 
6 B). 
Morpholog~ of Activated Monocytes.  Con  A  supernatant-treated  monocytes  were 
larger, more spread, and  more stretched out  than nonactivated monocytes (Fig.  7). 
Activated monocytes covered 1.8 times the surface area of nonactivated monocytes on 
petri dishes. 
Supernatant-activated Monocytes Inhibit L. pneumophila Multiplication Both by Phagocytosing 
Fewer Bacteria and by Slowing the Rate of Intracellular Multiplication.  Activated mononu- 
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FIG.  6.  A. Monocytes progressively lose their responsiveness to supernatant with time in culture. 
Freshly explanted monocytes in monolayer culture were maintained in RPMI  1640 medium and 
15% fresh normal human serum. Starting 0, 3, 7, or  10 d after explantation, replicate cultures were 
treated  daily with either Con  A-induced supernatant  (200 /.d, i.e.,  10%  of petri  dish volume) or 
control medium. The monocytes were infected 24 h  after their first treatment (i.e.,  1, 4, 8, or  11 d 
after  explantation),  and  CFU  determined  daily.  The  stippled  area  represents  the  range  of L. 
pneumophila CFU  in control  monocytes, and the lines represent  L. pneumophila CFU  in monocytes 
treated with Con A-induced supernatant. Each point represents the average for three replicate petri 
dishes ::I:SE. B. Nonactivated monocytes lose spontaneous inhibitory capacity with time in culture. 
Data for CFU in control monoeyte cultures during the first 24 h  after infection from Fig. 6 A are 
presented. Monocytes in culture for 0 d  (i.e.,  freshly explanted) and monocytes in culture 3,  7, and 
I0 d  (stippled area)  were treated  with control  medium for 24 h  and infected with L. pneumophila. 
The number of CFU per culture was determined at the time of infection and 24 h  later. MARCUS HORWITZ AND SAMUEL SILVERSTEIN  1627 
Ftc.  7.  The morphology  of monocytes  changes with activation. Freshly explanted monocytes in 
monolayer culture were incubated in RPMI 1640 medium containing 15% fresh normal human 
serum and either 10% control medium (left) or Con A-induced  supernatant (right). After  48 h, both 
control and supernatant-activated monocytes  were fixed and photographed at the same magnifi- 
cation, using a phase contrast microscope  (× 850). 
clear phagocytes have been reported to have a  diminished phagocytic capacity for a 
number of particles including several intracellular pathogens (see Discussion). Because 
L.  pneumophila must  enter  monocytes in  order  to  multiply,  one  way  supernatant- 
activated monocytes might inhibit  L. pneumophila multiplication is by phagocytosing 
fewer bacteria. To examine this question, we compared the phagocytic capacities of 
supernatant-activated and control monocytes by two independent methods within a 
single experiment. First, we compared monocytes treated with Con A-induced super- 
natant  or control medium  for their capacity to bind or ingest  viable L. pneumophila 
bacteria,  as  measured  by  CFU.  We  incubated  the  monocyte monolayers with  L. 
pneumophila for  2  h,  washed  away  nonadherent  bacteria,  counted  the  number  of 
monocytes in each petri dish, lysed the monocytes by sonication, measured CFU per 
dish,  and calculated CFU per monocyte. It was important  to count the number of 
adherent  monocytes because the supernatant-activated monocytes adhered better to 
petri dishes than the control monocytes when the monolayers were washed to remove 
nonadherent  bacteria  (Table  I,  line  A);  enhanced  adherence  of activated  human 
monocytes to a  degree comparable to what we observed has been reported by others 
(7). Control experiments showed that, immediately after washing, >85% of CFU were 
cell-associated by the criterion  that  they were released  into the medium only when 
the monocytes were lysed by sonication. 
Second,  we  compared  replicate  cultures  of  supernatant-activated  and  control 
monocytes for their  capacity to bind  or ingest  L. pneumophila bacterial  particles,  as 
measured by fluorescence microscopy. We incubated the monocyte monolayers with 
L. pneumophila and washed them as above, fixed them, stained them with fluorescein- 1628  ACTIVATED MONOCYTES INHIBIT LEGIONELLA MULTIPLICATION 
TABLE  I 
Supematant-activated Monocytes Inhibit L. pneumophila Multiplication Both by Phagocytosing Fewer 
Bacteria and Slowing Intracellular Multiplication 
Control monocytes  Activated monocytes 
(experiment  1)*  (experiment  1) 
Effect  of activation 
Experiment  Experi-  Experiment 
1  ment 2  3 
Mean 
A.  L. pneumophila CFU/monocyte 
1.  Monocytes/petri dish  344,000  ±  14,000  650,000  ±  37,000  ~l.9X:~  T1.6x  TI.6x  ~l.7X 
2.  CFU/petri dish  1,340 ±  118  1,560 ±  168 
3.  CFU/monocyte  3.90 X  10  -a  2.40 X  10  -3  ~38%:~  ~,52%  ~67%  ,~52.3~7, 
B.  L. pneumophila particles/monocyte 
1.  Monocytes counted  2,243  2,059 
2.  Percent rnonocytes  with :"1 
particle  9.6%  6.1%  ,~36%§  ,~54%  ~50%  J,46.7% 
3.  Total particles counted  259  147 
4.  Particles/monocyte  115 x  10  -3  71 x  10  -3  ~38%§  ~,60%  ~63%  ~53.7'7c 
C.  Doubling  time  of  L.  pneumophila 
during first 22 h after infection 
I.  CFU/petri dish (t w 0)  1,340 ±  118  1,560 ±  168 
2.  CFU/petri dish (t =  22 h)  192,000 ±  88,000  7,275 ±  4 
3.  Doubling time  3.1 h  10.0h  ~3.2x:~  ~3.2X  J'3.0X  T3.1x 
Freshly explanted monocytes in monolayer culture were treated for 24 h with 400/~1 (20% by volume) Con 
A-induced supernatant or control medium in petri dishes, four of which contained coverslips. The cultures 
were  then  incubated  with  L.  pneumophila for  2  h  and  washed  to  remove  nonadherent  bacteria. 
A. Immediately thereafter, supernatant-activated monocytes in three petri dishes and control monocytes in 
three petri dishes were counted (AI), lysed by sonication,  and CFU per petri dish determined (A2). Data 
are the average for three dishes  +SE. From these data,  the average number of CFU per monoeyte was 
calculated  (A3). B.  Also  immediately thereafter, supernatant-activated  monocytes  in  two  dishes  (each 
containing three coverslips)  and control monocytes  in  two dishes  (also with three coverslips  each)  were 
fixed, stained with fluorescein-conjugated  rabbit anti-L, pneumophila  antibody, and examined by fluorescence 
microscopy. The percentage of >2,000 consecutive supernatant-activated and control monocytes with one 
or more L. pneumophila  particle(s)  (B 1 and B2) and the total number of monoeyte-associated  particles (B3) 
were enumerated. From these data, the average number of particles/monocyte was calculated (B4). C. 22 
h after infection,  supernatant-treated monocytes  in three petri dishes and control monocytes in three petri 
dishes were lysed by sonication and CFU per petri dish were determined (C2). Using data obtained in A 
(C1),  the  mean  doubling  time of L. pneumophila in  supernatant-activated  and  control  monocytes was 
calculated as described  in Materials and Methods (C3). 
* Detailed  data  are  presented  for  one  experiment  (experiment  1)  under  columns  headed  "Control 
monocytes" and  "Activated monocytes." The  data  for  that  experiment  and  two  other  experiments 
(experiment  2 and experiment 3) are summarized and averaged in columns under the heading "Effect of 
activation." 
activated monocyte data 
~: Factor = 
control monocyte data 
control monocyte data -  activated monocyte data 
§ Percent  x  100 
control monocyte data 
conjugated  rabbit  anti-L,  pneumophila  antibody,  examined  then  by  fluorescence  mi- 
croscopy, and counted  the number  of bacterial  particles per monocyte. 
Supernatant-activated  monocytes  bound  or  ingested  fewer  L.  pneumophila  than 
control  monocytes  as  determined  by  assaying  either  monocyte-associated  CFU  or 
monocyte-associated  fluorescent  bacterial  particles  (Table  I).  In  three  experiments, 
supernatant-activated  monocytes bound  or ingested an average of 52.3%  fewer CFU 
and  53.7%  fewer  fluorescent  bacterial  particles  (Table  I).  Within  each  experiment, 
the two assays yielded similar results. 
To determine whether supernatant-activated  and control monocytes phagocytosed 
these  monocyte-associated  bacteria,  we examined  the monocytes by electron micros- MARCUS HORWITZ AND SAMUEL SILVERSTEIN  1629 
copy. In the same experiment as above, we infected replicate monocyte monolayers 
with L. pneumophila grown on agar for 72 h. We used once-passed (i.e., egg yolk passed 
to agar once) agar-grown organisms because we could obtain them in high number 
and thereby achieve a  high particle:monocyte ratio during infection; the high ratio 
was  required  to  obtain  an  adequate  number  of monocyte-associated bacteria  in 
random ultrathin sections of adherent monocytes. Control experiments showed that 
such once-passed agar-grown bacteria multiply in human monocytes and that their 
multiplication is inhibited in supernatant-activated monocytes. By electron micros- 
copy, all monocyte-associated bacteria were intracellular in membrane bound vacu- 
oles, whether in supernatant-activated or control monocytes. 
These experiments showed that supernatant-activated monocytes phagocytose fewer 
L. pneumophila bacteria than control monocytes. To determine if supernatant-activated 
monocytes also  slow  the  rate  of intracellular  multiplication  of L.  pneumophila, we 
determined, in the same experiment, the doubling time of monocyte-associated (i.e., 
intracellular) bacteria during the first 22 h after infection from the data described in 
Table I C. During this 22-h period, L. pneumophila multiplication occurred predomi- 
nantly or exclusively in the initially infected monocytes, which were initially lightly 
infected;  by  fluorescence  microscopy,  >97%  of control  monocytes  and  >99%  of 
supernatant-activated  monocytes with  cell-associated  bacterial  particles  contained 
two or fewer bacterial particles  (not all of which were viable)  and none contained 
more than four. Control experiments showed that at both 0 and 22 h after infection, 
>85% of the CFU in dishes were monocyte associated by the criterion that they were 
released into the medium only when the monocytes were lysed by sonication. 
The  doubling  time  of L.  pneumophila was  markedly  prolonged  in  supernatant- 
activated monocytes in comparison to control monocytes (Table I). In three experi- 
ments,  the  doubling  time was  prolonged an  average of 3.1  times  in  supernatant- 
activated cells. 
Thus, supernatant-activated monocytes inhibit L. pneumophila multiplication by two 
mechanisms. They restrict access of bacteria to the intracellular milieu the bacteria 
require for multiplication, and they slow the multiplication rate of those bacteria that 
are internalized. 
Antibody Does Not Augment the Capacity of Supernatant-activated Monocytes to Inhibit L. 
pneumophila multiplication.  We determined the doubling time of L. pneumophila during 
the first 22 h after infection in supernatant-activated and control monocytes as above, 
except that  we preincubated the bacteria in  50%  immune or normal  fresh human 
serum  before  infection,  and  maintained  the  monocytes in  the  presence  of a  10% 
concentration of the corresponding immune or control serum throughout the experi- 
ment. In supernatant-activated monocytes, the doubling time of antibody-coated L. 
pneumophila (9.6 h) did not differ significantly from the doubling time of L. pneumophila 
not treated with specific antibody (9.9 h). 
Monocytes Activated with  Con A-induced Supernatant Do Not  Kill L.  pneumophila.  To 
determine  whether  monocytes treated  with  Con  A-induced  supernatant  have  the 
capacity to kill L. pneumophila, we incubated mononuclear cells in test tubes with or 
without  Con  A-induced  supernatant  for  24  h.  Control  experiments  showed  that 
monocytes in such cultures resemble monocytes similarly incubated in  petri dishes 
with respect to their capacity to support or inhibit L. pneumophila multiplication (data 
not shown). After 24 h, we added Con A-induced supernatant to control cultures and 1630  ACTIVATED  MONOCYTES  INHIBIT  LEGIONELLA  MULTIPI,ICATION 
immediately incubated  the mononuclear cells with L. pneumophila for 2  h  in shaking 
suspension in the presence of normal or immune serum. We then lysed the leukocytes 
by sonication and determined CFU in the medium. 
In  the  presence  of  normal  seurm,  containing  complement  but  not  antibody, 
monocytes did not kill L. pneumophila regardless of whether or not the monocytes were 
activated  (Fig. 8).  In the presence of immune serum, containing both anti-L, pneumo- 
phila antibody and complement, both activated and nonactivated monocytes killed L. 
pneumophila, but they killed only a small proportion (0.2 log) of the original inoculum. 
The activated  monocytes did  not kill more L. pneumophila; in  fact,  they consistently 
killed fewer bacteria than nonactivated monocytes, perhaps because they phagocytose 
less avidly. Thus, Con A-induced supernatant endows the monocytes with the capacity 
to inhibit the multiplication of L. pneumophila but not to kill them. 
Discussion 
Cell-mediated immunity may be viewed as having an afferent arm--the induction 
of cytokines, including  lymphokines, that  activate mononuctear phagocytes,  and an 
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Fie;.  8.  Monocytes  activated with Con  A-induced supernatant do  not  kill L. pneumophila. Mona- 
nuclear cells  (6  X  106) were  incubated  in  RPMI  1640  medium  containing fresh  normal human 
serum with or without  Con  A-induced supernatant.  After 24  h,  Con  A-induced supernatant was 
added  to  cultures  not  initially  treated  with  it.  Then,  L.  pneumophila (106  CFU)  that  had  been 
preincubated for  10 rain at 37°C with either 25% normal or 25% immune fresh human serum were 
added to each tube along with additional serum of the same type. The cultures were incubated for 
2  h  at  37°C  in  5~7~ CO2-95'7~  air on  a  gyratory shaker, after which  the'leukocytes were  lysed  by 
sonication and CFU of L. pneumophila in the medium determined. Each point represents the average 
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efferent  arm--the  expression  of cytotoxic activity by  the  activated  mononuclear 
phagocytes. A number of intracellular parasites have been reported to be susceptible 
to the efferent arm of cell-mediated immunity. Activated mononuclear phagocytes, 
particularly animal macrophages, have been reported to kill or inhibit the multipli- 
cation of Leishmania enriettii (8, 9), Toxoplasma gondii (10-15), T~ypanosoma cruzi (16,  17), 
Rickettsia tsutsugamushi (18),  Coxiella burnetti (19),  and the bacterial pathogens Listeria 
monocytogenes (20-23)  and Mycobacterium tuberculosis (24, 25).  Our studies show that L. 
pneumophila is also susceptible to the efferent arm of cell-mediated immunity and that 
activated human monocytes are capable of inhibiting the intracellular multiplication 
of this bacterium. 
Our studies do not indicate whether L. pneumophila antigens induce cell-mediated 
immunity, i.e., induce sensitized mononuclear cells to produce cytokines capable of 
activating mononuclear phagocytes to an antimicrobial capacity. However, in guinea 
pigs, L. pneumophila antigens have been  reported to induce cutaneous delayed-type 
hypersensitivity (26),  a  correlate  of cell-mediated  immunity. Thus,  L.  pneumophila 
provokes a  specific cell-mediated immune response in animal hosts. It seems likely 
that it also does so in man. 
We  have  referred  in  this  paper  to  the  activating molecules  in  Con  A-induced 
supernatant as cytokines because we do not know which cells in the mononuclear cell 
population  produce  them.  In  studies  of  the  mononuclear  cells  involved  in  the 
production of cytokines, the lymphocyte has been shown to be essential. Similarly, in 
our study the production of Con A-induced cytokine was lymphocyte dependent (Fig. 
1). Where it has been examined, these lymphocytes have been reported to be T  cells 
(8,  12, 13, 15, 23). 
With  time  in  culture,  human  monocytes lost  both  spontaneous  and  cytokine- 
dependent capacity to inhibit L. pneumophila multiplication; that is, monocytes became 
progressively less inhibitory to L. pneumophila multiplication (Fig. 6 B) and they lost 
their  capacity  to  respond  to  Con  A-induced  supernatant  with  a  slowing  of L. 
pneumophila multiplication  (Fig.  6 A).  Loss of spontaneous and cytokine-dependent 
inhibitory capacities  have been  observed  in  studies of anti-tumor cell activities of 
mouse macrophages (27, 28). The time course for loss of cytokine-dependent antimi- 
crobial activity in our study is similar to the time course for loss ofcytokine-dependent 
anti-tumor cell activity in one of these studies (27). Interestingly, the time course for 
loss of spontaneous antimicrobial activity by human monocytes in our study is similar 
to  the  time-course  for  loss  of  hydrogen  peroxide  releasing  capacity  by  human 
monocytes in a study by Nakagawara et al. (29). 
Our studies show that activated human monocytes inhibit L. pneumophila multipli- 
cation in two ways. First, the activated monocytes phagocytose fewer bacteria and 
thereby restrict  access  of the  bacteria  to  the  intracellular milieu  they require  for 
multiplication. Second, these monocytes slow the rate of multiplication of bacteria 
that are internalized. Both of these phenomena, decreased phagocytosis and decreased 
rate  of multiplication of intracellular parasites,  have  been  observed  previously in 
activated mononuclear phagocytes, howbeit under separate circumstances. Although 
decreased phagocytosis has not been uniformly observed (30), in vivo activated mouse 
or guinea pig macrophages have been reported to exhibit decreased phagocytosis of 
starch  granules,  latex beads,  graphite  dust,  and  formalinized L.  monocytogenes (30), 
sheep erythrocytes coated with IgG or with IgM and complement (31),  T. cruzi (32), 1632  ACTIVATED  MONOCYTES INHIBIT LEGIONEI,I~A MULTIPLICATION 
Candida albicans (33),  Cryptococcus neoformans (34),  and  R.  tsutsugamushi (18);  in  vitro 
activated human monocytes have been reported to exhibit decreased phagocytosis of 
latex particles  (35).  Thus, decreasing phagocytosis and decreasing the rate of intra- 
cellular multiplication of pathogens may be general mechanisms by which activated 
mononuclear phagocytes defend the host against intracellular pathogens. 
In  this  and  previous  papers  (2,  3),  we  have  investigated  the  potential  roles  of 
humoral and cell-mediated immunity in  Legionnaires' disease.  Humoral immunity 
appears to play a limited role in host defense against Legionnaires' disease. Antibody 
and  complement promote a  modest amount of killing of virulent L. pneumophila by 
human  polymorphonuclear leukocytes and  monocytes, but  these  humoral  compo- 
nents, which promote entry of L. pneumophila into monocytes, do not inhibit the rate 
of  L.  pneumophila multiplication  in  monocytes  (2,  3).  In  contrast,  cell-mediated 
immunity appears to play a major role in host defense against  Legionnaires' disease. 
Activated human monocytes inhibit the intracellular multiplication of L. pneumophila. 
Thus,  inhibition  of L. pneumophila multiplication  in  monocytes is  accomplished by 
activating the monocytes and not by coating the bacteria with antibody and comple- 
ment. 
Legionnaires' disease has a predilection for immunocompromised patients (36-39). 
Our findings suggest that a defect in cell-mediated immunity may be responsible for 
this by rendering such patients less capable of limiting the multiplication of Legion- 
naires' disease bacteria to which they are exposed. 
In the normal host, humoral and cell-mediated immunity may work in concert to 
eliminate L. pneumophila bacteria. However, humoral immunity in the absence of cell- 
mediated immunity theoretically could endanger the host by targeting L. pneumophila 
to monocytes where the bacteria multiply (1, 3). This could occur in both the normal 
and immunocompromised host.  In the normal host, this might occur from immuni- 
zation with a vaccine that resulted only in antibody production. In an immunocom- 
promised host with intact humoral but impaired cell-mediated immunity, this might 
occur from immunization  (even with  a  vaccine that  in  a  normal  individual  would 
induce both antibody production and cell-mediated immunity), or from prior expo- 
sure to Legionnaires' disease. 
Summary 
We have examined the interaction between virulent egg yolk-grown L. pneumophila, 
Philadelphia  1 strain, and in vitro-activated human monocytes, under antibiotic-free 
conditions.  Freshly explanted human  monocytes activated by incubation with con- 
canavalin A  (Con A) and human lymphocytes inhibited the intracellular multiplica- 
tion of L. pneumophila. Both Con A and lymphocytes were required for activation. Con 
A was consistently maximally effective at -->4/~g/ml. 
Monocytes activated by incubation with cell-free filtered supernatant from Con A- 
sensitized mononuclear cell cultures also inhibited the intracellular multiplication of 
L. pneumophil  a.  The  most  potent  supernatant  was  obtained  from  mononuclear cell 
cultures incubated with -> 15/~g/ml Con A for 48 h. The degree ofmonocyte inhibition 
of L. pneumophila multiplication was proportional to the length of time monocytes were 
preincubated  with  supernatant  (48  >  24  >  12  h)  and  to  the  concentration  of 
supernatant added (40% >  20% >  10% >  5%).  Monocytes treated with supernatant 
daily  were  more  inhibitory  than  monocytes  treated  initially  only.  With  time  in MARCUS  HORWITZ AND SAMUEL  SILVERSTEIN  1633 
culture,  monocytes  progressively  lost  a  limited  degree  of spontaneous  inhibitory 
capacity and also lost their capacity to respond to supernatant  with inhibition  of L. 
pneumophila multiplication. 
Supernatant-activated  monocytes  inhibited  L.  pneumophila  multiplication  in  two 
ways.  They phagocytosed  fewer  bacteria,  and  they slowed  the  rate  of intracellular 
multiplication  of bacteria  that were internalized.  As was the case with nonactivated 
monocytes,  antibody  had  no  effect  on  the  rate  of intracellular  multiplication  in 
supernatant-activated  monocytes. 
Neither supernatant-activated  nor nonactivated monocytes killed L. pneumophila in 
the  absence  of antibody.  Both  killed  a  limited  proportion  of these  bacteria  in  the 
presence of antibody and complement. 
We  have  previously  reported  that  anti-L,  pneumophila  antibody  and  complement 
neither  promote  effective  killing  of L.  pneumophila  by  human  polymorphonuclear 
leukocytes  and  monocytes  nor  inhibit  the  rate  of L.  pneumophila  multiplication  in 
monocytes. These findings and our present report that activated monocytes do inhibit 
L. pneumophila multiplication indicate that cell-mediated immunity plays a major role 
in host defense against  Legionnaires' disease. 
We are grateful to Ms. Diane Chodkowski for excellent technical assistance. 
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